Nanobody-based recombinant antivenom for cobra, mamba and rinkhals bites.

ABSTRACT: Each year, snakebite envenoming claims thousands of lives and causes severe injury to victims across sub-Saharan Africa, many of whom depend on antivenoms derived from animal plasma as their sole treatment option¹. Traditional antivenoms are expensive, can cause adverse immunological reactions, offer limited efficacy against local tissue damage and are often ineffective against all medically relevant snake species². There is thus an urgent unmet medical need for innovation in snakebite envenoming therapy. However, developing broad-spectrum treatments is highly challenging owing to the vast diversity of venomous snakes and the complex and variable composition of their venoms³. Here we addressed this challenge by immunizing an alpaca and a llama with the veno

SUBMITTER: Ahmadi S 

PROVIDER: S-EPMC12629983 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature